Centessa Pharmaceuticals (CNTA) Equity Average: 2022-2025
Historic Equity Average for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $323.2 million.
- Centessa Pharmaceuticals' Equity Average fell 17.76% to $323.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.2 million, marking a year-over-year decrease of 17.76%. This contributed to the annual value of $318.9 million for FY2024, which is 11.42% up from last year.
- Per Centessa Pharmaceuticals' latest filing, its Equity Average stood at $323.2 million for Q3 2025, which was down 11.58% from $365.6 million recorded in Q2 2025.
- Centessa Pharmaceuticals' 5-year Equity Average high stood at $450.3 million for Q4 2024, and its period low was $225.7 million during Q1 2024.
- Its 3-year average for Equity Average is $319.8 million, with a median of $314.7 million in 2023.
- Its Equity Average has fluctuated over the past 5 years, first slumped by 36.69% in 2023, then soared by 81.72% in 2024.
- Centessa Pharmaceuticals' Equity Average (Quarterly) stood at $354.5 million in 2022, then plummeted by 30.10% to $247.8 million in 2023, then surged by 81.72% to $450.3 million in 2024, then decreased by 17.76% to $323.2 million in 2025.
- Its Equity Average stands at $323.2 million for Q3 2025, versus $365.6 million for Q2 2025 and $393.9 million for Q1 2025.